Healthcare >> Analyst Interviews >> February 19, 2001

Outlook For Biotechnology Stocks: Fariba Ghodsian – Roth Capital Partners

FARIBA F. GHODSIAN is currently Managing Director and Director of Healthcare Research at Roth Capital Partners, where she provides coverage of the biotechnology industry and is involved in public and private financing for biotechnology companies. She has been an active member of the financial and scientific communities for over 15 years, having held positions of Scientist, Director of Business Development, acting Chief Financial Officer, and Board member for privately and publicly held biotechnology and pharmaceutical companies, such as Allergan, MedClone, and Trega Biosciences. Most recently, she worked as Vice President and Senior Biotechnology Analyst for several investment- banking firms, such as Lehman Brothers, Hancock Institutional (Sutro and Tucker Anthony) and Wedbush Morgan Securities. Dr. Ghodsian is a well- published author, holds several patents, and has served on the Scientific Grant Review Board of the National Institutes of Health. She has also been a frequent guest speaker in investment and industry conferences and on television programs about biotechnology industry trends and investments. Dr. Ghodsian is a founding Board member of the Southern California Biomedical Council and serves on the Board of Trustees of the American Technion Society. Dr. Ghodsian received her MBA from UCLA (Beta Gamma Sigma), postdoctoral fellowship from Harvard Medical School, PhD in Biomedical Engineering from Oxford University, MS in Chemical Engineering from MIT, and BS in Chemical Engineering from Technion, Israel Institute of Technology. Profile
TWST: Looking at the biotech companies, give us an overview and an

outlook based on events, issues and trends in the last 12 months that

have set the stage for the next 12 months.